Goldman Sachs Reaffirms Neutral Rating on Cochlear (COH)
Cochlear (ASX: COH)‘s stock had its “neutral” rating restated by equities researchers at Goldman Sachs in a report issued on Monday. They currently have a $67.71 (65 AUD) target price on the stock.
Cochlear remained flat at A$74.770 during trading on Monday. Cochlear has a 52-week low of A$51.310 and a 52-week high of A$71.790. The company has a market cap of A$4.252 billion and a price-to-earnings ratio of 74.92.
Separately, analysts at Nomura reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Tuesday, October 30th. They now have a $70.31 price target on the stock.
Cochlear Limited (Cochlear) is an Australia-based company, which operates in the implantable hearing device industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
As the shareholders in Germany opposes the re-election of Mr Flint as Chairman and Mr Gulliver CEO of HSBC Holdings ...
Since Obama seems to never know anything about any issue at any given time on any given subject from any ...
a one year high of $63.82? On May 15th?
What a nonsense, the shares were at $77.11!
There is an expectation of an easing of the Australian dollar which will help Cochlear. There is also an expectation of an announcement that the company will be making available a recalled product publically available again in the near future. Cochlear is being prudent in taking its time to put its Nucleus implant through the most rigorous of tests before bringing it back onto the market. In this game, reputation for reliability and responsiveness to any the slightest hint of a problem (qualities that have been demonstrated by Cochlear) is paramount.